Access to Fludrocortisone tablets for all CAH Communities


Despite Fludrocortisone and Hydrocortisone tablets both being included on the World Health Organisation's Essential Medicines List for Children (WHO EMLc) in 2008, both drugs are still hard for Congenital Adrenal Hyperplasia (CAH) communities in low- and middle-income countries to access.

In 2008 CLAN was proud to partner with David Beran and the International Insulin Foundation (IIF) to examine access to hydrocortisone and fludrocortisone tablets in Vietnam in more detail, and our RAPIA report on that process is available here.

Internationally, CLAN continues to partner with many different groups to find solutions to affordable access to the growing international CAH Community, and we are pleased that progress is being made, although we are aware that access to fludrocortisone tablets remains a major burden for most communities.

CLAN is pleased to share that two key opportunities are emerging and are working in partnership with APPES (the Asia Pacific Pediatric Endocrinology Society) and others on a couple of key solutions for families in the Asia Pacific region. If your community is not able to access fludrocortisone locally, we would suggest your doctors contact us at or APPES directly to find out more. Alternatively, if your community is based in Africa or Latin America, we suggest you connect with GPED (Global Pediatric Endocrinology and Diabetes).